InMed Pharmaceuticals Inc. (INM)
| Market Cap | 5.76M +32.6% |
| Revenue (ttm) | n/a |
| Net Income | -12.13M |
| EPS | -3.13 |
| Shares Out | 4.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,135 |
| Open | 1.330 |
| Previous Close | 1.310 |
| Day's Range | 1.290 - 1.350 |
| 52-Week Range | 0.575 - 2.500 |
| Beta | 0.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 9, 2026 |
About INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids ... [Read more]
Financial Performance
Financial StatementsNews
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Pharmaceuticals Annual report: Q4 2026
InMed Pharmaceuticals has published its Q4 2026 annual report on September 9, 2026.
InMed Pharmaceuticals Earnings release: Q4 2026
InMed Pharmaceuticals released its Q4 2026 earnings on September 9, 2026, summarizing the period's financial results.
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 millio...
InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
InMed Pharmaceuticals (INM) announced that it has entered into an amendment to the previously announced definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-...
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered in...
InMed regains compliance with Nasdaq continued listing requirements
InMed Pharmaceuticals (INM) announced that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on June 3, 2026 informing the company that it…
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing ...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InM...
InMed Pharmaceuticals Transcript: M&A announcement
The merger creates a $421M all-stock company focused on advancing novel migraine therapies, supported by $290M in new funding and expected to close in H2 2026. The combined entity aims to address unmet needs in the growing migraine market.
InMed Pharmaceuticals Press release: M&A announcement
InMed Pharmaceuticals issued a press release on May 19, 2026, disclosing material business information to investors.
InMed Pharmaceuticals and Mentari announce merger for migraine prevention
InMed Pharmaceuticals (INM) has entered into a definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company developing therapies for migra...
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubs...
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propriet...
InMed Pharmaceuticals Quarterly report: Q3 2026
InMed Pharmaceuticals has published its Q3 2026 quarterly earnings report on May 6, 2026.
InMed Pharmaceuticals Earnings release: Q3 2026
InMed Pharmaceuticals released its Q3 2026 earnings on May 6, 2026, summarizing the period's financial results.
InMed receives Nasdaq notification regarding minimum bid price compliance
InMed Pharmaceuticals (INM) announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market dated March 27, 2026, notifying it that the closing bi...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifyin...
InMed Pharmaceuticals announces preclinical data on effects of INM-901
InMed Pharmaceuticals (INM) announced new preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer’s disease. These studies, c...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimen...
InMed Pharmaceuticals files $50M mixed securities shelf
17:02 EDT InMed Pharmaceuticals (INM) files $50M mixed securities shelf
InMed Pharmaceuticals Registration statement: Registration filing
InMed Pharmaceuticals filed a registration statement on March 20, 2026, providing details about a securities offering with the SEC.
InMed Pharmaceuticals Transcript: Sidoti March Small-Cap Virtual Conference
Lead drug INM-901 showed strong preclinical efficacy in Alzheimer's models, reducing neuroinflammation and improving cognition, with a pre-IND FDA meeting planned for Q3 and clinical trials targeted for 2027. INM-089 and INM-755 also advance in eye and skin disease, supported by robust IP and a $7M cash position.
InMed Pharmaceuticals provides development outlook for 2026
InMed Pharmaceuticals (INM) provides a pharmaceutical development outlook for 2026. 2026 Development Priorities for INM-901 include: Conduct a pre-IND meeting with the U.S. Food and Drug Administratio...